3 Stocks Pushing The Health Services Industry Higher
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our modelAll three major indices are trading down today with the Dow Jones Industrial Average (^DJI) trading down 9 points (-0.1%) at 14,437 as of Tuesday, March 12, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,094 issues advancing vs. 1,829 declining with 130 unchanged.The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.3%. Top gainers within the industry include Life Technologies (LIFE), up 2.3%, Aetna (AET), up 1.5%, UnitedHealth Group (UNH), up 1.2%, Smith & Nephew (SNN), up 0.8% and WellPoint (WLP), up 0.5%. On the negative front, top decliners within the industry include Intuitive Surgical (ISRG), down 1.0%, Baxter International (BAX), down 0.8% and Edwards Life (EW), down 0.5%.TheStreet Ratings group would like to highlight 3 stocks pushing the industry higher today:3. DexCom (DXCM) is one of the companies pushing the Health Services industry higher today. As of noon trading, DexCom is up $0.97 (6.2%) to $16.54 on heavy volume Thus far, 448,186 shares of DexCom exchanged hands as compared to its average daily volume of 373,400 shares. The stock has ranged in price between $15.78-$16.63 after having opened the day at $15.81 as compared to the previous trading day's close of $15.57. DexCom, Inc., a medical device company, engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of diabetic and non-diabetic patients. DexCom has a market cap of $1.1 billion and is part of the health care sector. Shares are up 17.4% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate DexCom a buy, no analysts rate it a sell, and 5 rate it a hold.TheStreet Ratings rates DexCom as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full DexCom Ratings Report now.It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE
Latest Headlines about STJ
-
St. Jude Medical Becomes #114 Most Shorted S&P 500 Component, Replacing Murphy Oil
02:55PM 05/10/13
-
St. Jude Medical Gets Too Much Praise
06:30AM 05/06/13
-
St. Jude Medical Becomes #173 Most Shorted S&P 500 Component, Replacing Fluor Corp.
03:02PM 04/10/13
-
Analysts' Actions: AIG MSFT SIRI MO LVS
09:12AM 01/10/13
-
5 Stocks Paying You Double-Digit Shareholder Yield
12:58PM 12/27/12
-
TheStreet Ratings Top 10 Rating Changes
03:02PM 12/10/12
-
Stocks Pare Losses, End Flat for the Day
04:41PM 11/30/12
Latest from TheStreet Wire
-
Infosys Ltd (INFY): Today's Featured Technology Laggard
05:01PM 05/24/13
-
Williams Companies Inc (WMB): Today's Featured Basic Materials Laggard
05:01PM 05/24/13
-
Trimble Navigation Limited (TRMB): Today's Featured Electronics Laggard
05:01PM 05/24/13
-
Deere & Co (DE): Today's Featured Industrial Laggard
05:01PM 05/24/13
-
Eli Lilly And Company (LLY): Today's Featured Drugs Laggard
05:01PM 05/24/13
-
Sap AG (SAP): Today's Featured Computer Software & Services Laggard
05:01PM 05/24/13
-
Duke Energy Corporation (DUK): Today's Featured Utilities Laggard
05:01PM 05/24/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
